DSM-Firmenich Croissance future
Future contrôle des critères 3/6
DSM-Firmenich devrait augmenter ses bénéfices et son chiffre d'affaires de 25.5% et de 5.4% par an respectivement. Le BPA devrait croître de de 25.5% par an. Le rendement des capitaux propres devrait être 6.2% dans 3 ans.
Informations clés
25.5%
Taux de croissance des bénéfices
25.54%
Taux de croissance du BPA
| Chemicals croissance des bénéfices | 16.0% |
| Taux de croissance des recettes | 5.4% |
| Rendement futur des capitaux propres | 6.24% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 06 Aug 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Aug 05
DSFIR: Elevated Multiple And Margin Uncertainty Will Pressure Future Share Buyback Support
DSM-Firmenich's analyst price target has moved from €60.56 to €67.00, with analysts pointing to higher assumed revenue growth, a slightly lower discount rate, and a higher future P/E multiple as they refresh their views following several upward price target revisions across the Street. Analyst Commentary Recent research on DSM-Firmenich shows a wide spread of views on the stock, with price targets ranging from the mid €60s through to above €100.
Mise à jour du récit • Jul 22
DSFIR: Share Repurchase Program Will Drive Bullish Re Rating Potential
The analyst price target for DSM-Firmenich has been raised from €103 to about €115. Analysts point to slightly higher assumed revenue growth, a modestly stronger profit margin profile, and a higher future P/E assumption as key drivers of the revised valuation.Mise à jour du récit • Jul 08
DSFIR: Share Buyback And Dual Listing Will Drive Re Rating Potential
The analyst price target for DSM-Firmenich has been revised to €103.00 from €98.68, with analysts pointing to updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E, along with a series of recent price target changes across the Street ranging from €60 to €99. Analyst Commentary Recent research on DSM-Firmenich shows a wide range of views, but there is a clear group of bullish analysts who see room for the stock to move closer to the upper end of current target ranges.
Mise à jour du récit • Jun 24
DSFIR: Share Buyback And New Listing Plan Will Shape Future Re Rating
The updated analyst price target for DSM-Firmenich now sits at €79.37, a marginal adjustment from €79.82. This reflects a blend of more cautious discounting and slightly revised assumptions on revenue growth, profitability, and future P/E as analysts react to recent mixed target changes across the Street.Mise à jour du récit • Jun 08
DSFIR: Share Buyback And Dual Listing Will Support Re Rating
Analysts have adjusted the DSM-Firmenich price target to reflect a slightly higher fair value, moving from about €98.08 to around €98.68, as recent research points to revised assumptions on revenue growth, profit margins and future P/E. This comes against a mixed backdrop of price target changes across the Street, including moves between €60 and €87.Mise à jour du récit • May 24
DSFIR: Reset Profitability Expectations Will Pressure Future Margin Resilience
Analysts have reduced the DSM-Firmenich fair value estimate to about €60.56, down from €67.00. This change reflects a series of lower price targets from several banks, along with more cautious assumptions for growth, margins and valuation multiples.Mise à jour du récit • May 09
DSFIR: Share Buyback Plan Will Support Re Rating Despite Mixed Earnings Views
DSM-Firmenich's updated analyst price target moves from €100.84 to €98.08, as analysts factor in slightly higher revenue growth and profit margin assumptions, along with a marginally higher discount rate and a lower future P/E, echoing recent mixed revisions across the Street. Analyst Commentary Recent research shows a mix of price target cuts and one later upward revision, which points to differing views on how quickly DSM-Firmenich can execute on its plans and how the current valuation lines up with earnings expectations.Mise à jour du récit • Apr 21
DSFIR: Share Buyback And Execution Discipline Will Support Future Re Rating
The analyst price target for DSM-Firmenich has been trimmed by around €2 to €79.82, reflecting analysts' recalibrated fair value assumptions after several recent target cuts and rating changes across the Street. Analyst Commentary Recent research updates on DSM-Firmenich point to a more cautious stance on valuation, with several firms revising price targets and ratings while still highlighting selective areas of support for the equity story.Mise à jour du récit • Apr 06
DSFIR: Share Buyback Plan Will Support Re Rating Despite Earnings Headwinds
The analyst price target for DSM-Firmenich is now more closely aligned with the recent Street range, moving from about €146 to roughly €101 as analysts factor in lower target prices, a slightly higher discount rate, and a more conservative future P/E multiple, despite updated revenue growth assumptions. Analyst Commentary Recent Street research on DSM-Firmenich centers on lower price targets and ratings changes, with analysts reassessing assumptions around earnings, consumer demand, and currency effects.Mise à jour du récit • Mar 23
DSFIR: Share Buyback And Market Share Defense Will Support Future Re Rating
DSM-Firmenich's analyst price target has been reduced by around €1.70 to €81.60, reflecting a series of recent target cuts and downgrades from banks as analysts factor in softer earnings expectations and a slightly lower profit margin outlook. Analyst Commentary Recent research updates show a clear reset in expectations for DSM-Firmenich, with several banks cutting price targets and some shifting to more neutral ratings as they reassess earnings power and valuation.Mise à jour du récit • Mar 09
DSFIR: Market Share Defense Will Offset Softer U.S. Demand And Currency Headwinds
We trim our fair value estimate for DSM-Firmenich to €83.30 from €96.62, reflecting a lower blended price target as analysts factor in softer U.S. consumer confidence, currency headwinds, and more muted medium term growth expectations, despite still supportive views from some houses. Analyst Commentary Recent Street research on DSM-Firmenich points to a more cautious stance on the shares, with several price target cuts and rating changes feeding into the reduced fair value estimate.Mise à jour du récit • Feb 22
DSFIR: Softer U.S. Demand And Full Valuation Will Shape Future Margin Resilience
Analysts have trimmed their fair value estimate for DSM-Firmenich to €67 from €70, reflecting lower price targets and more cautious earnings assumptions tied to softer U.S. consumer confidence, currency headwinds, and what they describe as a full valuation with limited EBITDA growth visibility into 2026. Analyst Commentary Recent Street research has turned more cautious on DSM-Firmenich, with several bearish analysts trimming price targets and moving to more neutral stances.Mise à jour du récit • Feb 08
DSFIR: Chinese Competition And Commoditization Risks Will Shape Future Margin Resilience
Analysts have reduced their fair value estimate for DSM-Firmenich to €70.00 from €71.89, reflecting lower price targets and more cautious views on growth potential and competitive pressures highlighted in recent research updates. Analyst Commentary Recent research has turned more cautious, with several bearish analysts trimming price targets and, in some cases, downgrading their stance on DSM-Firmenich.Mise à jour du récit • Jan 25
DSFIR: Market Share Defense Will Counter Rising European Commoditization Risk
The analyst fair value estimate for DSM-Firmenich has been reduced from €100.20 to €96.62, as analysts factor in lower assumed revenue growth and profit margins, slightly higher discount rates, and recent Street research highlighting full valuation, limited EBITDA growth prospects in 2026, and rising commoditization risks in European consumer ingredients. Analyst Commentary Recent Street research on DSM-Firmenich points to a more balanced view of the shares, with several firms trimming price targets and some shifting to more neutral stances.Mise à jour du récit • Jan 10
DSFIR: Market Share Defense Will Offset European Commoditization And Chinese Pricing Pressures
We have trimmed our fair value estimate for DSM-Firmenich from €102.00 to €100.20, reflecting analysts' lower price targets, slightly higher discount rate assumptions, and more cautious profit margin expectations, even as they factor in revised longer term revenue growth and P/E inputs. Analyst Commentary Recent Street research on DSM-Firmenich has turned more mixed, with several firms trimming price targets and shifting ratings as they reassess upside versus execution risks.Mise à jour du récit • Dec 14
DSFIR Commoditization And Chinese Competition Will Shape Future Margin Resilience Narrative
Analysts have reduced their average price target for DSM-Firmenich by roughly EUR 15, reflecting heightened concern over commoditization risks in European consumer ingredients, as well as intensifying competitive and pricing pressures from China. Analyst Commentary Bearish analysts have increasingly framed the recent wave of price target cuts as a reassessment of DSM-Firmenich's near term earnings power, with lower expectations for margin resilience in consumer ingredients.Mise à jour du récit • Nov 29
DSFIR: Market Share Defense Will Overcome Mounting European Competition Risks
Analysts have reduced their price targets for DSM-Firmenich by notable amounts, with recent estimates moving downward. Concerns about increased competition and pricing pressure are weighing on sentiment.Article d’analyse • Nov 26
DSM-Firmenich AG's (AMS:DSFIR) Shareholders Might Be Looking For Exit
When close to half the companies in the Chemicals industry in the Netherlands have price-to-sales ratios (or "P/S...Mise à jour du récit • Nov 15
DSFIR: Competitive Risks Will Ease As European Pricing Pressure Moderates
The analyst fair value target for DSM-Firmenich has been lowered from €105.70 to €102.00. Analysts cite concerns about increased commoditization risks, competitive pressure, and adjustments to growth and profitability outlooks.Mise à jour du récit • Nov 01
DSFIR: Resilient Consumer Health Demand Will Drive Performance Amid Pricing Pressure
Analysts have reduced their price target for DSM-Firmenich from €108.45 to €105.70. They cite slightly lower revenue growth expectations and modest adjustments to valuation assumptions as the reasons for this change.Article d’analyse • Oct 19
Is It Time To Consider Buying DSM-Firmenich AG (AMS:DSFIR)?
Today we're going to take a look at the well-established DSM-Firmenich AG ( AMS:DSFIR ). The company's stock received a...Mise à jour du récit • Oct 18
Health And Bio-Based Trends Will Drive Future Success
The fair value estimate for DSM-Firmenich has been slightly reduced from €108.95 to €108.45. This change reflects updated analyst projections citing modest adjustments to revenue growth and profit margin expectations.Mise à jour du récit • Oct 04
Health And Bio-Based Trends Will Drive Future Success
Analysts have lowered their price target for DSM-Firmenich from €114.65 to €108.95. They cite reduced expectations for revenue growth and a higher discount rate, despite a marginal improvement in profit margins and future valuation metrics.Article d’analyse • Sep 28
DSM-Firmenich (AMS:DSFIR) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Mise à jour du récit • Sep 19
Health And Bio-Based Trends Will Drive Future Success
Consensus price targets for DSM-Firmenich have been revised downward due to persistent earnings headwinds, weaker-than-expected Nutrition demand, and margin pressures from currency and input costs, partially offset by confidence in long-term synergies and portfolio optimization, resulting in a new fair value of €114.65 (down from €117.70). Analyst Commentary Bearish analysts point to persistent earnings headwinds and industry-wide pricing pressure driving down near-term profitability.Mise à jour du récit • Sep 04
Health And Bio-Based Trends Will Drive Future Success
With both the future P/E ratio and consensus revenue growth forecasts remaining essentially unchanged, analysts have maintained DSM-Firmenich’s fair value estimate at €117.70. What's in the News DSM-Firmenich launched Lacteol® diarrhEase™ Kids, a top pediatrician-recommended postbiotic for children as young as six months, in the U.S. market.
Nouveau récit • Feb 23
Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
The merger of DSM and Firmenich focuses on high-growth segments, enhancing revenue through synergies and achieving significant earnings improvements.Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 10,309 | 767 | 1,094 | 1,653 | 18 |
| 12/31/2027 | 9,725 | 641 | 973 | 1,485 | 19 |
| 12/31/2026 | 9,297 | 466 | 781 | 1,352 | 15 |
| 6/30/2026 | 9,055 | 324 | 825 | 1,650 | N/A |
| 3/31/2026 | 9,045 | 299 | 753 | 1,548 | N/A |
| 12/31/2025 | 9,034 | 274 | 681 | 1,445 | N/A |
| 6/30/2025 | 7,399 | 425 | 762 | 1,590 | N/A |
| 3/31/2025 | 8,227 | 363 | 888 | 1,684 | N/A |
| 12/31/2024 | 9,054 | 301 | 1,014 | 1,778 | N/A |
| 9/30/2024 | 12,627 | 30 | 876 | 1,615 | N/A |
| 6/30/2024 | 12,455 | -190 | 745 | 1,452 | N/A |
| 3/31/2024 | 11,541 | -424 | 659 | 1,359 | N/A |
| 12/31/2023 | 10,627 | -658 | 573 | 1,265 | N/A |
| 9/30/2023 | 9,686 | -456 | 434 | 1,112 | N/A |
| 6/30/2023 | 8,745 | -254 | 287 | 959 | N/A |
| 3/31/2023 | 8,568 | 100 | 301 | 962 | N/A |
| 12/31/2022 | 8,390 | 454 | 314 | 965 | N/A |
| 9/30/2022 | 9,582 | 837 | 412 | 1,056 | N/A |
| 6/30/2022 | 7,867 | 823 | 510 | 1,147 | N/A |
| 3/31/2022 | 7,568 | 822 | 680 | 1,287 | N/A |
| 12/31/2021 | 7,269 | 820 | 850 | 1,427 | N/A |
| 9/30/2021 | 7,955 | 660 | 884 | 1,507 | N/A |
| 6/30/2021 | 7,558 | 493 | 906 | 1,489 | N/A |
| 3/31/2021 | 7,572 | 423 | 906 | 1,497 | N/A |
| 12/31/2020 | 8,106 | 448 | 868 | 1,494 | N/A |
| 9/30/2020 | 7,960 | 510 | 809 | 1,434 | N/A |
| 6/30/2020 | 8,034 | 557 | 810 | 1,462 | N/A |
| 3/31/2020 | 9,011 | 722 | N/A | 1,471 | N/A |
| 12/31/2019 | 7,998 | 675 | N/A | 1,385 | N/A |
| 9/30/2019 | 8,272 | 820 | N/A | 1,399 | N/A |
| 6/30/2019 | 8,502 | 794 | N/A | 1,395 | N/A |
| 3/31/2019 | 9,124 | 934 | N/A | 1,282 | N/A |
| 12/31/2018 | 9,267 | 1,069 | N/A | 1,391 | N/A |
| 9/30/2018 | 9,235 | 984 | N/A | 1,310 | N/A |
| 6/30/2018 | 9,106 | 2,082 | N/A | 1,170 | N/A |
| 3/31/2018 | 8,908 | 1,942 | N/A | 1,110 | N/A |
| 12/31/2017 | 8,632 | 1,761 | N/A | 996 | N/A |
| 9/30/2017 | 8,471 | 1,676 | N/A | 993 | N/A |
| 6/30/2017 | 8,333 | 738 | N/A | 1,028 | N/A |
| 3/31/2017 | 8,166 | 711 | N/A | 1,077 | N/A |
| 12/31/2016 | 7,920 | 645 | N/A | 1,018 | N/A |
| 9/30/2016 | 7,831 | 588 | N/A | 958 | N/A |
| 6/30/2016 | 7,778 | 274 | N/A | 914 | N/A |
| 3/31/2016 | 7,749 | 214 | N/A | 811 | N/A |
| 12/31/2015 | 7,722 | 174 | N/A | 696 | N/A |
| 9/30/2015 | 7,607 | 66 | N/A | 800 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de DSFIR ( 25.5% par an) est supérieure au taux d'épargne ( 2.3% ).
Bénéfices vs marché: Les bénéfices de DSFIR ( 25.5% par an) devraient croître plus rapidement que le marché Dutch ( 17.4% par an).
Croissance élevée des bénéfices: Les bénéfices de DSFIR devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de DSFIR ( 5.4% par an) devrait croître plus lentement que le marché de Dutch ( 10.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de DSFIR ( 5.4% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de DSFIR devrait être faible dans 3 ans ( 6.2 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/06 21:38 |
| Cours de l'action en fin de journée | 2026/08/06 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
DSM-Firmenich AG est couverte par 44 analystes. 19 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jennifer Barker | Barclays |
| Alexander Sloane | Barclays |
| Sebastian Bray | Berenberg |